Halozyme Therapeutics Inc (NASDAQ: HALO) started the day on Wednesday, with a price increase of 2.12% at $45.76, before settling in for the price of $44.81 at the close. Taking a more long-term approach, HALO posted a 52-week range of $33.15-$65.53.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that the giant of the Healthcare sector posted annual sales growth of 41.16% over the last 5 years. Nevertheless, stock’s Earnings Per Share (EPS) this year is 43.80%. This publicly-traded company’s shares outstanding now amounts to $126.77 million, simultaneously with a float of $125.86 million. The organization now has a market capitalization sitting at $5.82 billion. At the time of writing, stock’s 50-day Moving Average stood at $55.15, while the 200-day Moving Average is $49.17.
Halozyme Therapeutics Inc (HALO) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Biotechnology Industry. Halozyme Therapeutics Inc’s current insider ownership accounts for 1.08%, in contrast to 99.28% institutional ownership. According to the most recent insider trade that took place on Oct 15 ’24, this organization’s SVP, CHIEF TECHNICAL OFFICER sold 10,000 shares at the rate of 53.75, making the entire transaction reach 537,469 in total value, affecting insider ownership by 173,756. Preceding that transaction, on Oct 16 ’24, Company’s SVP, CHIEF TECHNICAL OFFICER sold 10,000 for 53.26, making the whole transaction’s value amount to 532,590. This particular insider is now the holder of 173,756 in total.
Halozyme Therapeutics Inc (HALO) Earnings and Revenue Records
Halozyme Therapeutics Inc’s EPS increase for this current 12-month fiscal period is 43.80% and is forecasted to reach 4.60 in the upcoming year.
Halozyme Therapeutics Inc (NASDAQ: HALO) Trading Performance Indicators
Let’s observe the current performance indicators for Halozyme Therapeutics Inc (HALO). It’s Quick Ratio in the last reported quarter now stands at 9.15. The Stock has managed to achieve an average true range (ATR) of 2.80. Alongside those numbers, its PE Ratio stands at $15.14, and its Beta score is 1.23. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 6.15. Similarly, its price to free cash flow for trailing twelve months is now 14.82.
In the same vein, HALO’s Diluted EPS (Earnings per Share) trailing twelve months is recorded 3.02, a figure that is expected to reach 1.17 in the next quarter, and analysts are predicting that it will be 4.60 at the market close of one year from today.
Technical Analysis of Halozyme Therapeutics Inc (HALO)
If we take a close look at the recent performances of Halozyme Therapeutics Inc (NASDAQ: HALO), its last 5-days Average volume was 4.32 million that shows progress from its year to date volume of 1.36 million. During the previous 9 days, stock’s Stochastic %D was recorded 11.78% While, its Average True Range was 3.10.
Raw Stochastic average of Halozyme Therapeutics Inc (HALO) in the period of the previous 100 days is set at 15.94%, which indicates a major fall in contrast to 18.64% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 104.00% that was higher than 50.94% volatility it exhibited in the past 100-days period.
